Blue Trust Inc. Has $355,000 Position in United Therapeutics Corporation $UTHR

Blue Trust Inc. boosted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 7.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,235 shares of the biotechnology company’s stock after buying an additional 86 shares during the period. Blue Trust Inc.’s holdings in United Therapeutics were worth $355,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at about $29,000. SVB Wealth LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at about $32,000. Geneos Wealth Management Inc. increased its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. Sound Income Strategies LLC acquired a new position in United Therapeutics in the 1st quarter valued at approximately $49,000. Finally, Brooklyn Investment Group increased its stake in United Therapeutics by 103.2% in the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 98 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on UTHR shares. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Oppenheimer upped their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of United Therapeutics in a research report on Wednesday, October 8th. Cantor Fitzgerald increased their price objective on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Finally, Wells Fargo & Company increased their price objective on United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a report on Wednesday, September 3rd. Ten equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $457.21.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $440.06 on Tuesday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48. The business’s 50-day simple moving average is $375.22 and its 200-day simple moving average is $324.71. The firm has a market cap of $19.85 billion, a price-to-earnings ratio of 17.18, a P/E/G ratio of 4.82 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same quarter last year, the business earned $5.85 EPS. The company’s revenue for the quarter was up 11.7% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at approximately $11,356,133.75. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 261,935 shares of company stock worth $105,561,472 over the last quarter. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.